Polarized scorpion venom solution and a method for making polarized scorpion venom solution

ABSTRACT

The present invention discloses a polarized dilute blue scorpion venom solution and a method for administering dilute scorpion venom solution. The polarized dilute scorpion venom solution provides treatment to various diseases and conditions such as relieving pain, improving immune-system responses, treating cancer, preventing cancer, improving quality of sleep, reducing inflammation, and minimizing negative biological response to chemotherapy and radiation treatment

This Application is a Continuation of U.S. Non-Provisional patentapplication Ser. No. 12/270,664, filed on Nov. 13, 2008, titled“Polarized Scorpion Venom Solution and a Method For Making PolarizedScorpion Venom”, by inventor Arthur Mikaelian, the contents of which areexpressly incorporated herein by this reference, and to which priorityis claimed. Priority is also claimed to U.S. Provisional PatentApplication Ser. No. 60/987,756, filed Nov. 13, 2007, titled “Analgesic,Antiinflammatory, Immunity Boosting, Antitumoral, and Cancer Preventingand Treating methodology Using Organic, Modified, and MagneticallyPolarized Scorpion Venom and Synthetics Thereof”, by inventor ArthurMikaelian, the contents of which are expressly incorporated herein bythis reference.

FIELD OF THE INVENTION

The invention generally relates to analgesic and anti-tumor solutions.Specifically, it pertains to a polarized dilute scorpion venom solution,a method for making a polarized dilute scorpion venom solution, and amethod for administering dilute scorpion venom solution. The polarizeddilute scorpion venom solution relieves pain, improves immune systemresponse, treats cancer, prevents cancer, improves quality of sleep,reduces inflammation, and minimizes negative biological response tochemotherapy and radiation treatment.

BACKGROUND OF THE INVENTION

Around the world, research is being done on the potential effectivenessof scorpion venom as a cancer-fighting tool. Scientists have taken asynthetic version of venom of Leiurus quinquestriatus, also known as theGiant Yellow Israeli scorpion, labeled it with radioactive iodine andfound it to be an effective delivery vehicle for targeted radiotherapyagainst glioma. The synthetic venom binds to glioma cells and has anunusual ability to pass through the blood-brain barrier that blocks mostsubstances from reaching brain tissue from the bloodstream. Thesynthetic venom is used primarily as a carrier to transport radioactiveiodine to glioma cells, but there is data that suggests that it may alsoslow down the growth of tumor cells.

Dr. M. A. A. Omran of Suez Canal University in Egypt published the study“Cytotoxic and apoptotic effects of scorpion Leiurus quinquestriatusvenom on 293T and C2C12 eukaryotic cell lines” in the Journal ofVenomous Animals and Toxins including Tropical Diseases. Dr. Omran'sstudy proves the venom from scorpions of the Buthidae family,particularly Leiurus quinquestriatus, produces apoptosis in human cells.The most intriguing element of Dr. Omran's study was that it showed thatscorpion venom produces both apoptosis (cellular suicide) and necrosis(cellular death through trauma). The key issue is concentration. Atcertain concentrations, scorpion venom resulted in apoptosis. In other,larger concentrations, cytotoxicity shifted to necrosis.

Like Leiurus quinquestriatus, Rhopalurus junceus (blue scorpion) belongsto the Buthidae family of scorpions. The blue scorpion is indigenous toEastern Cuba, Venezuela, Haiti, and the Dominican Republic. Bluescorpion venom, has been used as a folk medicine in Eastern Cuba forgenerations. It was found that in a certain areas of Cuba when peoplewho had chronic conditions were stung by the blue scorpion, theirconditions surprisingly improved instead of getting worse. In 1980, bluescorpion venom was researched in the Cuban province of Guantanamo, oneof the areas where the blue scorpion is indigenous. Originally thechemicals taken from the blue scorpion were used primarily to treatailments in animals. The effects upon animals were found to beextraordinary. Doctors then began to consider the positive impact itcould have upon the health of humans. In the early 1990's, blue scorpionvenom was tested on a human patient and was found to shrink, and theneliminate, the tumor of a young Cuban woman. Ever since that event ithas been in use as an aggressive treatment for anti-tumor therapy.

Recently, blue scorpion venom has been shown to have a variety of healthbenefits including powerful analgesic and anti-inflammatory effects. Inaddition to cancer, blue scorpion venom has been shown to have positiveresults with a wide variety of immune-system related diseases including:HIV; Alzheimer's Disease; Multiple Sclerosis; Muscular Dystrophy; andArthritis. During the last 15 years, over 60,000 people outside theUnited States have taken blue scorpion venom and witnessed greatimprovements in their lives.

Although blue scorpion venom has been used in the past to treat pain,inflammation, cancer, and other ailments the delivery systems andscorpion venom solutions themselves have been inconsistent. This madeadministration of an effective blue scorpion venom solution difficult.Thus, there is a need in the art for a blue scorpion venom solution thatis stable, safe, effective, and consistent.

Moreover, blue scorpion venom, like many liquids, is most effective whenit is polarized.

A polarized liquid, as compared to non-polarized liquid, is absorbed farmore rapidly into the human body and is significantly more bio-availableon a cellular level, resulting in significantly improved results. Thishas been tested in small scale blind studies in which the cases did notknow whether or not they were receiving unpolarized liquid or polarizedliquid. In those cases where individuals actually receivedpolarized/magnetized liquid, they reported significantly improvedresults over those individuals who received non-polarized liquid. It isbelieved that the effects of the polarization process stays effectivelywithin the liquid for three to four weeks before the liquid returns to astate similar to pre-polarization. To polarize scorpion venom, the venomis repeatedly exposed to fixed magnetic fields aligns the magnetic polesof the molecules within the scorpion venom liquid in such a way that itforms a geometric consistency between the molecules which influences thebody's ability to recognize the liquid and open molecular gates forbetter absorption. This process preferably utilizes fixed magnets;however, electromagnets may also be used. This process is an integralpart of the solution and method of the current invention and isexplained in more detail below.

As discussed above, blue scorpion venom provides benefits to the humanbody through apoptosis. Apoptosis is a biological mechanism throughwhich cytotoxicity takes place. Apoptosis diminishes unhealthyinflammatory response, improves efficacy of chemotherapy, supportsgrowth of healthy cellular tissue, and is essential to the body'snatural ability to destroy cancerous tumors.

The process of apoptosis a major focus of research and the developmentof new pharmaceutical drugs for the treatment of: cancer; HIV;arthritis; multiple Sclerosis; Alzheimer's Disease; a wide range ofother auto-immune conditions; and supporting appropriate immune systemresponse to organ transplants.

Because apoptosis is the primary mechanism by which blue scorpion venomrelieves pain, improves immune-system response, treats cancer, preventscancer, improves quality of sleep, reduces inflammation, and minimizesnegative biological response to chemotherapy and radiation treatment, anexpanded understanding of apoptosis is required. The role of cellularsuicide in the formation of embryonic cells has been recognized for agreat deal of time, but what was not understood was the crucial rolecellular suicide plays in healthy biological function. The differencesbetween cellular suicide and necrosis are well documented. Necrosisoccurs when a cell becomes acutely injured and ruptures, causinginflammatory cells to rush in to clear away the debris. Programmed cellsuicide, in contrast, is clean, quick, and involves a predictablesequence of structural changes that cause a cell to shrink and then berapidly digested by neighboring cells. This programmed cell suicideprocess is called apoptosis.

Additionally, research has been done that shows that apoptosis isgenetically controlled. Furthermore, the link between apoptosis andcancer is well established.

Over the last 20 years, using emerging technologies, scientists haveconfirmed that apoptosis plays a central role within developingorganisms by shaping the neural and immune systems and molding tissuespecificity. They also demonstrated that apoptosis helps to establish anatural balance between cell death and cell renewal in mature animals bydestroying excess, damaged, or abnormal cells. Mounting evidenceindicates that the acquired ability to resist apoptosis is a hallmark ofmost, and perhaps all, types of cancer. As scientists learn more abouthow apoptosis is thwarted by cancer, they are also gaining a greaterunderstanding of why many tumors are resistant to the cellularsuicide-inducing effects of radiation and chemotherapy. Researchers areexploring how apoptosis is regulated and how it can be selectivelytriggered, through tailored treatments, to induce suicide in cancercells while leaving healthy cells alone.

To better understand apoptosis, necrosis must also be understood. Cellsthat are damaged by injury, such as by mechanical damage or exposure totoxic chemicals, undergo a characteristic series of changes, including:they (and their organelles, like mitochondria) swell (because theability of the plasma membrane to control the passage of ions and wateris disrupted); and the cell contents leak out, leading to inflammationof surrounding tissues.

By contrast cells that are induced to commit suicide (apoptosis):shrink; develop bubble-like blebs on their surface; have the chromatin(DNA and protein) in their nucleus degraded; have their mitochondriabreak down with the release of cytochrome c; break into small,membrane-wrapped, fragments; the phospholipid phosphatidylserine, whichis normally hidden within the plasma membrane, is exposed on thesurface; the cell fragments are bound by receptors on phagocytic cellslike macrophages and dendritic cells, which then engulf the cellfragments; and the phagocytic cells secrete cytokines that inhibitinflammation (e.g., IL-10 and TGF-.beta.). The line of events in deathby suicide is so orderly that the process is often called programmedcellular death.

There are two different reasons why cells typically commit suicide.First, programmed cell death is as needed for proper development asmitosis is. For example: the resorption of the tadpole tail at the timeof its metamorphosis into a frog occurs by apoptosis; the formation ofthe fingers and toes of the fetus requires the removal, by apoptosis, ofthe tissue between them; the sloughing off of the inner lining of theuterus (the endometrium) at the start of menstruation occurs byapoptosis; and the formation of the proper connections (synapses)between neurons in the brain requires that surplus cells be eliminatedby apoptosis. Second, programmed cell death is needed to destroy cellsthat represent a threat to the integrity of the organism. For example:cells infected with viruses. Indeed, one of the methods by whichcytotoxic T lymphocytes (CTLs) kill virus-infected cells is by inducingapoptosis. Moreover, as cell-mediated immune responses wane, theeffector cells must be removed to prevent them from attacking bodyconstituents. CTLs induce apoptosis in each other and even inthemselves. Defects in the apoptotic machinery are associated withautoimmune diseases such as lupus erythematosus and rheumatoidarthritis.

Cells with DNA damage. Damage to its genome can cause a cell to disruptproper embryonic development leading to birth defects or becomecancerous. Cells respond to DNA damage by increasing their production ofa protein called p53. p53 is a potent inducer of apoptosis. Mutations inthe p53 gene frequently cause a defective protein to be produced. Thesemutated p53 genes are often found in cancer cells and these cancer cellsrepresent a lethal threat to the organism if permitted to live.

Cancer cells. Radiation and chemicals used in cancer therapy induceapoptosis in some types of cancer cells. Radiation and chemotherapycause apoptosis by withdrawing positive signals; that is, signals neededfor continued survival, or by sending negative signals.

Withdrawal of positive signals. The continued survival of most cellsrequires that they receive continuous stimulation from other cells and,for many, continued adhesion to the surface on which they are growing.Some examples of positive signals: growth factors for neurons; andInterleukin-2 (IL-2), an essential factor for the mitosis oflymphocytes.

Receipt of negative signals cause: increased levels of oxidants withinthe cell; damage to DNA by these oxidants or other agents likeultraviolet light, x-rays, and chemotherapeutic drugs; accumulation ofproteins that failed to fold properly into their proper tertiarystructure; molecules that bind to specific receptors on the cell surfaceand signal the cell to begin the apoptosis program. These deathactivators include: tumor necrosis factor-alpha (TNF-.alpha.) that bindsto the TNF receptor; lymphotoxin (also known as TNF-.beta.) that alsobinds to the TNF receptor; and Fas ligand (FasL), a molecule that bindsto a cell-surface receptor named Fas (also called CD95).

The Mechanisms of Apoptosis. There are 3 different mechanisms by which acell commits suicide by apoptosis. The first is generated by signalsarising within the cell (internal signals). The second is triggered bydeath activators binding to receptors at the cell surface, such asTNF-.alpha., Lymphotoxin, and Fas ligand (FasL). The third is reactiveoxygen.

Apoptosis triggered by internal signals involves the intrinsic ormitochondrial pathway. In a healthy cell, the outer membranes of itsmitochondria display the protein Bcl-2 on their surface. Internal damageto the cell (e.g., from a reactive oxygen species) causes Bcl-2 toactivate a related protein, Bax, which punches holes in the outermitochondrial membrane, causing cytochrome c to leak out. The releasedcytochrome c binds to the protein Apaf-1 (“apoptotic protease activatingfactor-1”). Using the energy provided by ATP, these complexes aggregateto form apoptosomes. The apoptosomes bind to and activate caspase-9.Caspase-9 is one of a family of over a dozen caspases. They are allproteases. They get their name because they cleave proteins, mostly eachother, at aspartic acid (Asp) residues. Caspase-9 cleaves and, in sodoing, activates other caspases (caspase-3 and -7). The activation ofthese “executioner” caspases creates an expanding cascade of proteolyticactivity (rather like that in blood clotting and complement activation)which leads to digestion of structural proteins in the cytoplasms,degradation of chromosomal DNA, and phagocytosis of the cell.

Apoptosis triggered by external signals involves the extrinsic or deathreceptor pathway. Fas and the TNF receptor are integral membraneproteins with their receptor domains exposed at the surface of the cell,binding of the complementary death activator (FasL and TNF respectively)transmits a signal to the cytoplasm that leads to activation of caspase8. Vaspase 8 (like caspase 9) initiates a cascade of caspase activationleading to phagocytosis of the cell.

When cytotoxic T cells recognize (bind to) their target, they producemore FasL at their surface. This binds with the Fas on the surface ofthe target cell leading to its death by apoptosis.

Apoptosis-inducing factor (AIF) is a protein that is normally located inthe inter-membrane space of mitochondria. When the cell receives asignal telling it that it is time to die, AIF is released from themitochondria (like the release of cytochrome c in the first pathway);migrates into the nucleus; binds to DNA, which triggers the destructionof the DNA and cell death.

Apoptosis and Cancer. Some viruses associated with cancers use tricks toprevent apoptosis of the cells they have transformed. Several humanpapilloma viruses (HPV) have been implicated in causing cervical cancer.One of them produces a protein (E6) that binds and inactivates theapoptosis promoter p53. Epstein-Barr Virus (EBV), the cause ofmononucleosis and associated with some lymphomas, produces a proteinsimilar to Bcl-2 and produces another protein that causes the cell toincrease its own production of Bcl-2. Both these actions make the cellmore resistant to apoptosis (thus enabling a cancer cell to continue toproliferate). Even cancer cells produced without the participation ofviruses may have tricks to avoid apoptosis. Some B-cell leukemias andlymphomas express high levels of Bcl-2, thus blocking apoptotic signalsthey may receive. The high levels result from a translocation of theBCL-2 gene into an enhancer region for antibody production. Melanoma(the most dangerous type of skin cancer) cells avoid apoptosis byinhibiting the expression of the gene encoding Apaf-1. Some cancercells, especially lung and colon cancer cells, secrete elevated levelsof a soluble “decoy” molecule that binds to FasL, plugging it up so itcannot bind Fas. Thus, cytotoxic T cells (CTL) cannot kill the cancercells by the mechanism shown above. Other cancer cells express highlevels of FasL, and can kill any cytotoxic T cells (CTL) that try tokill them because CTL also express Fas (but are protected from their ownFasL).

Apoptosis in the Immune System. The immune response to a foreign invaderinvolves the proliferation of lymphocytes, T and/or B cells. When theirjob is done, they must be removed leaving only a small population, ofmemory cells. This is done by apoptosis. Very rarely humans areencountered with genetic defects in apoptosis. The most common one is amutation in the gene for Fas, but mutations in the gene for FasL or evenone of the caspases are occasionally seen. In all cases, the geneticproblem produces autoimmune lymphoproliferative syndrome or ALPS. Thefeatures of ALPS include: an accumulation of lymphocytes in the lymphnodes and spleen greatly enlarging them; the appearance of clones thatare autoreactive, that is, attack “self” components producing suchautoimmune disorders as hemolytic anemia and thrombocytopenia; and theappearance of lymphoma, a cancerous clone of lymphocytes. In mostpatients with ALPS, the mutation is present in the germline; that is,every cell in their body carries it. In a few cases, however, themutation is somatic; that is, has occurred in a precursor cell in thebone marrow. These later patients are genetic mosaics, with somelymphocytes that undergo apoptosis normally and others that do not. Thelatter tend to out-compete the former and grow to become the majorpopulation in the lymph nodes and blood.

Apoptosis and AIDS. HIV (human immunodeficiency virus) invades CD4+ Tcells, and one might assume that it this infection by HIV that causesthe great dying-off of these cells. However, that appears not to themain culprit. Fewer than 1 in 100,000 CD4+ T cells in the blood of AIDS(acquired immunodeficiency syndrome) patients are actually infected withthe virus any uninfected CD4+ cells. The hallmark of AIDS is the declinein the number of the patient's CD4+ T cells (normally about 1000 permicroliter (.mu.l) of blood). CD4+ T cells are responsible, directly orindirectly (as helper cells), for all immune responses. When theirnumber declines below about 200 per .mu.l, the patient is no longer ableto mount effective immune responses and begins to suffer a series ofdangerous infections. The cause of the disappearance of CD4+ T cells isclear: apoptosis. The actual mechanism is not as clear. One mechanismmay be: all T cells, both infected and uninfected, express Fas; theexpression of a HIV gene (called Nef) in a HIV-infected cell causes thecell to express high levels of FasL at its surface while preventing aninteraction with its own Fas from causing it to self-destruct. However,when the infected T cell encounters an uninfected one (e.g. in a lymphnode), the interaction of FasL with Fas on the uninfected cell kills itby apoptosis.

Apoptosis and organ transplants. For many years it has been known thatcertain parts of the body such as the anterior chamber of the eye andthe testes have antigens that fail to elicit an immune response. Thisfinding raises the possibility of a new way of preventing graftrejection. If at least some of the cells on a transplanted kidney,liver, heart, etc. could be made to express high levels of FasL, whichmight protect the graft from attack by the T cells of the host'scell-mediated immune system. If so, then the present need for treatmentwith immunosuppressive drugs for the rest of the transplant recipient'slife would be reduced or eliminated. So far, the results in animalexperiments have been mixed. Allografts engineered to express FasL haveshown increased survival for kidneys but not for hearts or islets ofLangerhans.

Apoptosis activation as a therapeutic strategy for cancer. Cell survivalis maintained by a balance between pro-apoptotic and anti-apoptoticstimuli. Dysregulation of apoptosis can disrupt the equilibrium betweencell growth and cell death and is an important step in the developmentof cancer. It is this understanding that has led to the investigation oftherapeutic activation of apoptosis in cancer cells as a potentialanticancer strategy.

The role of p53 protein in apoptosis. Chemotherapy/radiotherapy-inducedand p53-mediated activation of apoptosis via the intrinsic signalingpathway. As prior research has found, the tumor suppressor protein p53is one of many proteins that contributes to the activation of theintrinsic signaling pathway. Inactivation of this protein or elements ofits attendant pathway (upstream activators and/or downstream effectors),due to mutation, is seen in as many as half of all human cancers.Because of the important role of p53 in the intrinsic apoptosis pathway,such a mutation can render tumor cells resistant to conventional radio-and chemotherapy. Current conventional therapies such as radio- andchemotherapy indirectly promote apoptosis, although this is an importantendpoint of the therapeutic effect. These regimens induce apoptosis bycausing DNA damage. In doing so, they stimulate apoptosis through theintrinsic pathway.

Apoptosis independent of p53. Promoting the alternative “extrinsic”apoptosis pathway, which operates independently of p53, or augmentingdownstream elements of the intrinsic apoptosis pathway, may have thepotential to induce apoptosis both in cancer cells that are responsiveand in those cancer cells that have become resistant to conventionaltherapies.

Apoptosis and naturally occurring chemicals. It has been shown that avariety of naturally occurring chemicals trigger apoptosis in humans,including Vitamins C and D. Extensive research has also shown thatcurcumin, a chemical from the culinary herb turmeric, also inducesapoptosis in humans. In recent years, a tremendous amount ofpharmaceutical research has turned its focus to natural venoms. Venomsof any kind are particularly intensely bioactive substances. Recently,peptides taken from the poison of the cone snail (Conus parius) havebeen approved by the FDA to be used as a treatment for chronic pain.These peptides, in the right concentration, have been shown to work aseffectively as morphine, but without any addictive qualities. Venom ofthe scorpion Leiurus quinquestriatus, from the Buthidae family, has hada great deal of research associated with its efficacy in treating braincancer. A great amount of research has been done over the last 15 yearsregarding scorpions of the Buthidae family and it has been shown, tovarying degrees, that the venom from this family produces apoptosis inhumans when administered in appropriate concentrations.

This research led to the present invention, a polarized dilute scorpionvenom solution, a method for making a polarized dilute scorpion venomsolution, and a method for administering dilute scorpion venom solution.The polarized dilute scorpion venom solution relieves pain, improvesimmune-system response, treats cancer, prevents cancer, improves qualityof sleep, reduces inflammation, and minimizes negative biologicalresponse to chemotherapy and radiation treatment.

SUMMARY OF THE INVENTION

To minimize the limitations in the prior art, and to minimize otherlimitations that will become apparent upon reading and understanding thepresent specification, the present invention is a ride that simulatesriding a rodeo bull or any other type of animal.

One embodiment of this invention is a solution, comprising: a bluescorpion venom; and a distilled water; wherein the solution ispolarized. Preferably, the blue scorpion venom is diluted with thedistilled water. Preferably, the diluted blue scorpion venom iscirculated through one or more plastic tubes. The one or more plastictubes should be aligned with one or more pairs of one or more magnets,and the alignment of the one or more pairs of the one or more magnetsshould mirror one or more negative poles and one or more positive polesof the one or more magnets, such that the one or more magnets repel eachother. Typically, the one or more magnets are compressed together with aclamp, such that the one or more magnets are held in place. The one ormore compressed magnets should compress the one or more plastic tubes,such that the diluted blue scorpion venom is forced to flow through theone or more plastic tubes. Typically, the polarized solution providesone or more benefits, selected from the group, consisting of: a paintreatment; a reduction of an inflammation; a prevention of a cancer; aprevention of a tumor growth; and a treatment of the cancer.

Another embodiment of the invention is a method of administering a bluescorpion venom, comprising the steps of: diluting a blue scorpion venom;polarizing the dilute blue scorpion venom; and administering thepolarized dilute blue scorpion venom to one or more humans. Preferably,the diluting step further comprises the steps of: adding a distilledwater to the blue scorpion venom to create a dilute blue scorpion venom.Preferably, the polarizing step further comprises the steps of:circulating the dilute blue scorpion venom solution through one or moreplastic tubes; placing one or more pairs of one or more magnets in aseries along the one or more plastic tubes; wherein the one or morepairs of the one or more magnets are placed on one or more oppositesides of the one or more plastic tubes; wherein the one or more magnetsare aligned, such that one or more negative poles and one or morepositive poles of the series of the pairs of the one or more magnetsmirror and repel each other; and compressing the series of the one ormore magnets with a clamp, such that the magnets remain in place;wherein the series of the one or more magnets are compressed with theone or more plastic tubes, such that the dilute blue scorpion venom isforced to flow through the one or more plastic tubes in close proximityto the one or more magnets. The administering step may be performed byingesting the polarized dilute blue scorpion venom by the one or morehumans. The administering step may be performed by spraying thepolarized dilute blue scorpion venom through a nasal cavity of the oneor more humans. The administering step may be performed by applying thepolarized dilute blue scorpion venom on a skin surface of the one ormore humans. The polarized dilute blue scorpion venom should provide oneor more benefits, selected from the group, consisting of: a paintreatment; a reduction of an inflammation; a prevention of a cancer; aprevention of a tumor growth; and a treatment of the cancer. Thepolarized dilute blue scorpion venom should boost an immune systemresponse of the one or more humans. The polarized dilute blue scorpionvenom should boost a level of an energy in the one or more humans.

Another embodiment of the present invention is a solution, comprising: ablue scorpion venom; and a distilled water. The blue scorpion venom isdiluted with the distilled water. The diluted blue scorpion venom iscirculated through one or more plastic tubes. The one or more plastictubes are aligned with one or more pairs of one or more magnets. Thealignment of the one or more pairs of the one or more magnets mirror oneor more negative poles and one or more positive poles of the one or moremagnets, such that the one or more magnets repel each other. The one ormore magnets are compressed together with a clamp, such that the one ormore magnets are held in place. The one or more compressed magnetscompress the one or more plastic tubes, such that the diluted bluescorpion venom is forced to flow through the one or more plastic tubes;and the polarized solution provides one or more benefits, selected fromthe group, consisting of: a pain treatment; a reduction of aninflammation; a prevention of a cancer; a prevention of a tumor growth;and a treatment of the cancer.

Another embodiment of the invention is a method of magneticallypolarizing blue scorpion venom, comprising the steps of: diluting a bluescorpion venom in a distilled water to create a dilute scorpion venomsolution; circulating the dilute scorpion venom solution through an oneor more plastic tubes; placing a series of flat magnets along the one ormore plastic tubes in pairs and on an one or more opposite sides of theone or more plastic tubes, wherein the series of flat magnets arealigned so that an one or more negative poles and an one or morepositive poles of the series of flat magnets mirror one another suchthat the series of flat magnets repel one another; compressing theseries of flat magnets together with a clamp so that the series of flatmagnets remain in place, wherein the series of flat magnets that arecompressed together also compress the one or more plastic tubes suchthat the dilute scorpion venom solution is forced to flow through theone or more plastic tubes in close proximity to the series of flatmagnets; and repeating the circulation step until the dilute scorpionvenom solution is polarized. The polarized scorpion venom solutiontreats pain, reduces inflammation, prevents cancer and tumor growth, andtreats cancer.

Another embodiment of the invention is a method of administering a bluescorpion venom, comprising the steps of: diluting the blue scorpionvenom; polarizing the dilute blue scorpion venom; and administering thepolarized dilute blue scorpion venom to humans. The blue scorpion venomis administered to humans orally. The blue scorpion venom reduces pain,reduces inflammation, prevents and treats cancer, boosts the immunesystem of a humans, and boosts the level of available energy.

An object of the present invention is to provide a scorpion venomsolution that relieves pain, reduces inflammation, boosts the immunityresponse, prevents cancer and tumor growth, treats cancer, reduces tumorgrowth, minimizes negative biological response to chemotherapy andradiation treatment, increases appetite and body mass duringchemotherapy and radiation treatment, and improves the quality of sleep.

Another object of the present invention is to provide a method ofpolarizing a blue scorpion venom solution that relieves pain, reducesinflammation, boosts the immunity response, prevents cancer and tumorgrowth, treats cancer, reduces tumor growth, minimizes negativebiological response to chemotherapy and radiation treatment, increasesappetite and body mass during chemotherapy and radiation treatment, andimproves the quality of sleep.

Another object of the present invention is to provide a polarized diluteblue scorpion venom solution that is safe, effective, easy to make, andeasy to administer.

Another object of the present invention is to provide a polarized diluteblue scorpion venom solution that may be used by a wide variety ofpeople regardless of their body size or individual characteristics.

Discussion on Safety. Dilute blue scorpion venom solution has been shownto be safe in numerous clinical trials. A fundamental different betweennecrosis and apoptosis is that in scientific studies necrosis has alwaysbeen shown to produce an inflammatory response. Apoptosis does notproduce an inflammatory response. In twenty-eight years of study of bluescorpion venom, it has never been shown to produce an inflammatoryresponse in adequate dosages. However, blue scorpion venom has beenshown to slow or reverse the growth of tumors with an 89.5% successrate. From this it may be concluded that blue scorpion venom producesapoptosis in cancer patients. Blue scorpion venom is a land-breakinginnovation in the fight against cancer. The primary reason for thisconclusion is that blue scorpion venom has undergone an eight year ThirdStage clinical trial involving 8,302 people, which showed that bluescorpion venom has no negative side effects, yet has an 89.5% successrate with cancer patients. This is unprecedented is the field ofoncology. In addition, because blue scorpion venom has shown extremelypotent analgesic and anti-inflammatory effects. Blue scorpion venomworks as an extraordinary compliment to traditional therapy including:surgery; chemotherapy; radiation; hormone therapy; and otherconventional treatments.

The following is a summary of the eight year, 8,302 patient Third StageClinical Trial. The information below is a summary of laboratory studycommissioned by the Cuban pharmacological company, Labiofirm, presentedby authors Alexis Diaz, Ph. D., Luis Morier, Yamira Caballero Lorenzo,Sergio Luis Yzquierdo Silverio, Sergio Luis Maestre Mesa, Ph. D.

Pre-clinical and clinical trials have shown that blue scorpion venom issafe and has no toxic side effects. High concentrations of blue scorpionvenom were administered in pre-clinical trials repeatedly over anextended period. Even with high concentrations of blue scorpion venom nonegative side effects were observed. During these pre-clinical trials,scientists recorded the following clinical signs to indicate the effectof blue scorpion venom. These clinical signs include: Normal MotorActivity; Healthy Reflexes; Response to Pain; Salivation;Sedation/Healthy Sleep; Responsiveness; Condition/Appearance of theSkin; Condition/Appearance of Mucous Membranes; Condition/Appearance ofthe Eyes; and Condition/Health of Internal Organs. Over the course ofthis study, all participants remained healthy. They maintained healthyweight and levels of activity. No harm was indicated to any of theinternal organs of those who participated in the study and all were inhealthy working order. In summary, it was scientifically determined thatblue scorpion venom has no toxic side effects.

Other features and advantages are inherent in the polarized dilute bluescorpion venom solution claimed and disclosed will become apparent tothose skilled in the art from the following detailed description and itsaccompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

The drawings are illustrative embodiments. They do not illustrate allembodiments. Other embodiments may be used in addition or instead.Details which may be apparent or unnecessary may be omitted to savespace or for more effective illustration. Some embodiments may bepracticed with additional components or steps and/or without all of thecomponents or steps which are illustrated. When the same numeral appearsin different drawings, it refers to the same or like components orsteps.

FIG. 1 is an illustration of the results of a study that shows theeffectiveness of blue scorpion venom as a pain killer.

FIG. 2 is an illustration of the results of a study that shows theeffectiveness of blue scorpion venom as an inflammation reducer.

FIG. 3 is an illustration of the results of a study that shows theeffectiveness of blue scorpion venom as a cancer fighter.

FIG. 4 is an illustration of the results of a study that shows theeffectiveness of blue scorpion venom as a cancer treatment in the body.

FIG. 5 is an illustration of the results of a study that shows theefficacy of the Makaelian Polarization Process.

FIG. 6 is an illustration of the results of a study that shows thequality of life for larynx cancer patients that used blue scorpionvenom.

FIG. 7 is an illustration of the results of a study that shows thequality of life for lung cancer patients that used blue scorpion venom.

FIG. 8 is an illustration of the results of a study that shows thequality of life for uterine cancer patients that used blue scorpionvenom.

FIG. 9 is an illustration of the results of a study that shows thesurvival rates for the sample types of cancer for patients that usedblue scorpion venom.

DETAILED DESCRIPTION OF THE DRAWINGS

In the following detailed description of various embodiments of theinvention, numerous specific details are set forth in order to provide athorough understanding of various aspects of one or more embodiments ofthe invention. However, one or more embodiments of the invention may bepracticed without some or all of these specific details. In otherinstances, well-known methods, procedures, and/or components have notbeen described in detail so as not to unnecessarily obscure aspects ofembodiments of the invention.

While multiple embodiments are disclosed, still other embodiments of thepresent invention will become apparent to those skilled in the art fromthe following detailed description, which shows and describesillustrative embodiments of the invention. As will be realized, theinvention is capable of modifications in various obvious aspects, allwithout departing from the spirit and scope of the present invention.Accordingly, the screen shot figures, and the detailed descriptionsthereof, are to be regarded as illustrative in nature and notrestrictive. Also, the reference or non-reference to a particularembodiment of the invention shall not be interpreted to limit the scopeof the invention.

This invention discloses a polarized dilute blue scorpion venom solutionacid a method to administer polarized dilute blue scorpion venomsolution to humans. As preferred, the active ingredient in the solutionis the venom of Rhopalurus junceus (blue scorpion). The venom ispreferably extracted from a bioterium of scorpions (Rhopalurusjunceus—blue scorpion) in order to obtain the quantity of venomnecessary to produce an organic, natural, and health supplement. Thebioterium preferably houses at least ten thousand (10,000) bluescorpions.

Scorpion acquisition and involved professional safety should beconsidered, and the preferred method is disclosed below. In addition,the captivity, handling, and feeding techniques are described, as wellas the method and equipment used for venom extraction. Because scorpionsare fragile and somewhat dangerous, a safe methodology to handle theanimals is preferred. Scorpion acquisition is preferably done byprofessionals with over 15 years experience in the acquisition, study,and maintenance of scorpions in bioteriums. Regular and appropriatefeeding of the animals should be maintained, along with regular cleaningof cages. Consequently, the survival of the animals preferably exceedsmultiple venom extractions. Controlled handling and more appropriatemaintenance of the scorpions will allow for higher survival rates, andbetter yields of venom.

Scorpion acquisition, preferably, starts in Haiti. The blue scorpionsshould then be imported to the bioterium. This first generation ofscorpions is preferably transported in protected units so that they willbe unable to escape into the environment. Animal quarantine will be doneby the rules and regulations as set forth by the country into which thebioterium is set up. All necessary tests indicating the health of thescorpions should be obtained through the appropriate ministries of theimporting country.

Personnel safety. The bioterium staff should be issued protective rubbergloves which will be impossible for the sting of Rhopalurus junceus(blue scorpion) to penetrate. The staff is preferably required to wearthis protective gear whenever they are in contact with the scorpions oron the grounds of the scorpion bioterium, thereby protective themselvesfrom injury. A LD 50 value of 8.0 mg/kg has been reported for the bluescorpion species. This indicates that the blue scorpion species is notamong the most venomous scorpions. This is a common scorpion in Haiti,and many people are stung each year. The only deaths that have beenreported are attributable to anaphylactic shock following ahypersensitivity immune reaction. Though the sting of Rhopalurus junceus(blue scorpion) is non-fatal and rarely elicits a severe physicalreaction, in case of a highly unusual allergic reaction to the bite,medication and antidote are preferably present and available at thescorpion bioterium at all times.

Environmental Safety. The acquired blue scorpions should be importedutilizing sealed, perforated boxes which will allow the scorpionssufficient air without providing any opportunity for escape. Oncetransported to the bioterium, the scorpions should be carefullytransferred individually into cages, preferably 50 centimeters wide by75 centimeters long by 40 centimeters high in size, and made of lightcolored polyethylene for easy visual monitoring. However, the cages canbe of any size, material or color without deviating from the scope ofthis invention. The corners of the boxes will be covered with plasticadhesive tape. This tape will prevent any scorpions from escaping. Thesecages will be stored a significant distance from any exits to thebuilding so that in the highly likely case that a scorpion should leaveits cage, the bioterium technicians will be able to see the animalbefore it has the possibility of escaping. Finally, each cage will benumbered with a count of the scorpions for that cage. This count will beverified at the beginning and end of each day to ensure that the correctnumber of scorpions is encaged and that there are no escaped animals.

Animal Safety. From acquisition to transportation to deposition in thebioterium, every effort should be made to ensure the safety andminimized stress of the animals. This is important because a stressedscorpion may not deliver as high a quality of venom. Great care shouldbe made to ensure that excessive movement does not occur of the travelcontainers holding the scorpions. Once deposited in the bioterium, thescorpions should be regularly monitored for health and levels of stress.Their cages should include natural items such as earth, sand, and bricksto better replicate a natural environment. Cages should be regularlycleaned and the scorpions fed a nutritious, all-natural diet.

Bioterium of scorpions preferably consists of one area covering twelve(12) square meters, and is preferably designed to keep spiders,scorpions, and insects in place and safe. The room should be equippedwith several windows that provide natural ventilation; heaters should beturned on during colder months to maintain the temperature between23-25.degree. C.

The animals, which arrive in the bioterium, are identified and selected:adult specimens, ready for venom extraction, are accommodated inappropriate cages according to first, second, third extraction, and soon. All the activities should be supervised and controlled by aprofessional in order to obtain satisfactory results. Birth of young inthe captivity is common. If there is a possibility of raising them, itis necessary to isolate the females and their progeny, and then theyoung from the mother.

The animals used in the venom production should be kept in differentcages. In order to maintain a productivity control, the animals fromdifferent extractions should never be mixed. Preferably the cages allowfor easy visual monitoring. Typically, commercially available boxes haverough corners that allow animals to escape. To avoid this, the cornersare covered with plastic adhesive tape. The cage floor is preferablycovered with a plate of waved cardboard to offer comfort to the animalsand avoid unnecessary stress. Layers of waved cardboard that areoverlaid and folded in accordion shape, increase the surface area of thehabitat and avoid excessive contact among the animals, preventingfrequent cannibalism. Cardboard offers appropriate protection since thescorpions show a high night activity. Further, cardboard is an extremelylight material, avoiding wound to the animals during handling. It isalso cheap and easy to find in the market. Water is supplied in plasticbowls (one in each cage), containing wet cotton. The cages are placed oniron shelves and covered with net lids framed with wood; they should belabeled accordingly. A control file should be kept beside each cage anddata such as entrance date, feeding, extraction, and death areregistered.

Maintenance is preferably performed weekly, and includes change ofcotton and cardboard, removal of dead animals and wash of each one ofthe boxes with water and neutral soap. Daily handling should be avoidedin order to decreasing animal stress. Other substrates such as earth,sand, bricks, and roof tile may also be used to imitate the naturalhabitat of the blue scorpion.

Feeding. The bioterium should be stocked with several kinds of insectsto feed all the animals in the bioterium. Food is offered to thescorpions once a week, after venom extraction, preferably consisting ofGryllus sp., Periplaneta americana, or Pycnocellus sp. (common roachesand crickets). The insects are kept in the cages for two days and thenthe cleaning is performed, removing all animals, washing the cages withwater and neutral soap, and changing cotton and cardboard. Every week,specimens from two or three cages are fed according to the foodavailability, assuring that each cage receives food at least every forty(40) to fifty (50) days a year. The quantity of food is calculatedaccording to the quantity of scorpions in each cage: preferably a roachfor every two animals, or an adult cricket for every animal.

Venom extraction is preferably performed every month. The scorpionsshould be milked for their venom on a monthly basis, preferably, byhighly trained staff. The venom is extracted by a mild electro-shockplaced briefly on the tail of the scorpion which encourages the scorpionto release its venom. This shock causes no physical damage to thescorpion, nor does it shorten the life span of the scorpion. The venomis then collected into a small cup and placed in refrigerated storage tomaintain the quality of the venom. Food is given a week after venomextraction in order to allow time for the animals to recover from anystress associated with the venom extraction. If they are fed before theextraction, the quantity of venom produced can be affected.

Storage and transportation of the venom. Once extracted, the venom ispreferably kept in a locked refrigeration unit. Preferably, the venom isregularly transported from the bioterium to a production facility. Ifthe production facility is in the United States it should be an FDAlicensed production facility. When transported, the venom is preferablymaintained in a temperature controlled, double-sealed container foradded safety and to maintain venom quality.

Production of the Dilute Scorpion Venom Solution.

As noted above, the first stage of production of the dilute scorpionvenom solution of the present invention is extraction. Individual“crops” of scorpions are extracted every 30 days. These crops are keptseparated from one another, but are given the same diet. Thisconsistency in diet, timing of extraction, and population control isintended to support consistency of concentration of venom per eachextraction.

Preferably, a one hundred milliliters (100 ml) glass container. Thecontainer can be empty, as preferred, or filled with of medicaldistilled water, which is used for extraction. Using electricalstimulation of each scorpion's tail, drops of scorpion venom will becaptured in this 100 ml glass container. Into each 100 ml container,approximately two hundred (200) drops of venom are extracted with anaverage of 2.55 drops from each scorpion.

The second step is transportation. Once extraction is completed, thecontainer is sealed and placed into a refrigerated environment. Thecontainer should be kept in that refrigerated environment for thirtyminutes until the venom reaches a maximum of twelve degrees centigrade(12 C (52 F)). At that time, the container should be packed into arefrigerated compartment which keeps an even temperature range between12 and 14 C (52-58 F) for 48 hours. These times and temperatures arepreferred, but a wide variety of times and temperatures are acceptablewithout deviating from the scope of the invention.

The third step is receiving. The manufacturing (preferablypharmaceutical) laboratory receives the concentrated venom solution.This concentrate should be brought to the laboratory facility. Thisconcentrate should be received in individual containers ranging in sizefrom 100 ml to 500 ml.

The fourth step is initial storage. The laboratory must immediatelyrefrigerate the concentrate. As noted above, the concentrate ispreferably received by the laboratory in a refrigerated container.Concentrate is preferably refrigerated and maintained at a range between12 to 14 C (52 F-58 F). The concentrate degrades at an accelerated ratewhen exposed to bright light; as such, this refrigerated storageenvironment should be protected from light and without internalillumination.

The fifth step is filtration. Scorpion venom is a complex mixture ofsalts, small molecules, peptides, and other proteins. The laboratoryshould filter the venom using glass fiber membrane filter that ispreferably 0.80 .mu.m, 25 mm, 1 pk/50 pcs. This ensures thesterilization and purification of the venom. The venom from a crop ofscorpions is extracted and filtered into a single, sterilized glasscontainer.

The sixth step is bulk manufacturing. After filtration, the venom iscombined with chilled, medical-quality distilled water to achieve aspecifically maintained concentration within a sterilized environment. Abulk version of the product is transferred into a sealed, sterilizedbulk container and the container then transferred into to a refrigeratedenvironment.

Determining the concentration. Typically, the dilute blue scorpion venomsolution contains 0.0003 ml of venom per 0.9997 ml of distilled water(totaling 1 ml of prepared dilute solution) for treatment of third andfourth stages of cancer. Concentration for treatment of baseline, first,and second stages of cancer is preferably 0.00025 ml of venom in 1 ml ofprepared dilute solution.

The final bulk dilute solution is preferably stored and shipped in adark and refrigerated environment.

The venom has tendency to separate from water when suspended in waterfor an extended period of time. To achieve consistent concentration ofvenom, the sealed bulk container is preferably agitated in a back andforth manner for no less than 30 minutes before being transferred intoindividual containers. During the packaging process the bulk containershould be continuously agitated through stirring.

The final step of the process is packaging and bottling. The bulkproduct is transferred in a sterilized environment into individual oneliter bottles, which should include labels, air-tight seals, and opaquecontainers, which protect the product from degradation due toinappropriate exposure to light. The containers are pre-sterilizedbefore being filled with the product. The process of packaging is timesensitive. Undo exposure to air and excessive temperatures willundermine the potency of the venom. As such, time is a sensitive issuewith the product. Exposed to room temperature, the process cannot beextended past a few (approximately four) hours from removal fromrefrigeration to completion of bottling. However, if bottling is done ina highly air conditioned environment (lower than 15 C or 58 F) or if thedistilled water used in production is chilled (through priorrefrigeration) then the period of production from removal fromrefrigeration to finalized bottling can be extended. Eight (8) hours forhighly chilled distilled water; twelve (12) hours for highlyrefrigerated environment.

Once the bottling procedure is complete, bottles of final product are tobe stored in a dark, refrigerated environment maintained, as preferred,at a temperature between 12 and 14 C (52 F and 58 F) where they willwait until final shipping.

The dilute blue scorpion venom is preferably tested for bacterialcontaminants, chemical contaminants, and concentration. Standardmicrobial and mass spectrometry tests are preferably used. If possible,no product should be shipped to a customer until the batch has undergonetesting for purity.

Standard testing procedures, such as Lowry's method for determiningprotein concentration should be used to quantitatively evaluate thedilute solution. Other types of procedures, known in the art, may alsobe used. Batches should be rejected if bacterial or chemicalcontaminants are found, or if more than 5% of the bottles test forlevels of any chemical naturally found within the venom, but at a higheror lower concentration in excess of 10% deviation from the standardconcentration per standardized mass spectrometry of the venom.

Polarization of the dilute scorpion venom solution. Preferably, thedilute solution is polarized. The preferred process for polarizing bluescorpion venom is the Mikaelian Polarized Liquid Process, named afterthe current inventor. The first steps in the polarization process,preferably, are to circulate the dilute scorpion venom solutionrepeatedly through plastic tubes. Preferably the plastic tubes are oneand a half (1.5) centimeters in diameter, but they can be any diameter,and can be made from any malleable, non-metallic material. Thecirculation is performed by one or more small pumps. The next step ofthe process is to place, along the pump or tubes, a series of flatmagnets. Preferably these magnets are placed in pairs along the oppositesides of the tubes and are aligned so that the negative poles andpositive poles of the magnets mirror one another so that the magnetsrepel one another. The magnets are then compressed with one or morenon-metallic, preferably wooden, clamps so that the magnets remain inplace. The magnets are compressed to within two millimeters of oneanother, also compressing the tubes so that the water must flow througha small gap between the magnets. Two millimeters is a preferredcompression point, any greater or lesser compression point may be used,so long as the liquid can flow within the tube, without deviating fromthe scope of the invention. Preferably, the scorpion venom dilution iscirculated through this tube lined with pairs of magnets for an extendedperiod of time. The resulting polarized liquid, compared tonon-polarized liquid, is absorbed far more rapidly into the human and issignificantly more bio-available on a cellular level, resulting insignificantly improved results.

FIG. 5, discussed below, discloses a study that showed how polarizedliquid is absorbed more rapidly into the body. The efficacy of polarizedliquid has been tested in small scale blind studies in which thesubjects did not know whether or not they were receiving unpolarizedliquid or polarized liquid. In those cases where individuals receivedpolarized/magnetized liquid, they reported significantly improvedresults. The effects of this Mikaelian polarization process stayseffectively within the liquid for three to four weeks before the liquidreturns to a state similar to pre-polarization. The Mikaelianpolarization process works through repeated exposure to fixed magneticfields that align the magnetic poles of the molecules within thescorpion venom liquid in such a way that it forms a geometricconsistency between the molecules which influences the body's ability torecognize the liquid and open molecular gates for better absorption.Typically fixed magnets are used however, electromagnets may also beused.

FIG. 1 is an illustration of the results of a study that shows theeffectiveness of blue scorpion venom as a pain killer. Blue scorpionvenom is a highly effective pain killer. In this study, several groupswere given different amounts of blue scorpion venom. Another group wasgiven a powerful, clinically used analgesic (paracetamol). Another group(a control group) was not given anything. As shown in FIG. 1, comparedto the control group (which received no pain killer), those participantswho were given paracetamol had 47% less pain. However, those given highconcentrations of blue scorpion venom had 55% less pain than those whowere not given any pain killers. Thus, it may be concluded that bluescorpion venom diminishes pain by 55%.

FIG. 2 is an illustration of the results of a study that shows theeffectiveness of blue scorpion venom as an inflammation reducer. Bluescorpion venom, as shown in FIG. 2, relieves inflammation. In the study,scientists created three groups. One group was given ananti-inflammatory steroid, (dexamet) often given to cancer patientsafter chemotherapy. Another group was not given anything. A third groupwas orally given blue scorpion venom. All three groups had inflammationartificially induced and were then observed. The level of inflammationwas recorded by weighing the participants before and after inflammationwas induced. Compared to the control group that received nothing, thosewho received blue scorpion venom had up to 38% less inflammation. Fromthis information, may be concluded that the blue scorpion venom solutionof the present invention, significantly reduces inflammation. Additionalinformation from other clinical trials strongly suggests that at higherdosages than were administered in pre-clinical trials, blue scorpionvenom's anti-inflammatory activity is even more powerfully enhanced.

FIG. 3 is an illustration of the results of a study that shows theeffectiveness of blue scorpion venom as a cancer fighter. As a part ofthe study, cancer cells from four different types of cancer were put intest tubes and then exposed to blue scorpion venom. For all types ofcancer used in the study, the number of cancer cells decreased afterbeing exposed to blue scorpion venom. One group decreased by 60% in justone week of exposure.

FIG. 4 is an illustration of the results of a study that shows theeffectiveness of blue scorpion venom as a cancer treatment in the body.As shown in FIG. 4, five groups had cancerous tumors. One group (thecontrol group) was not given anything. The other four groups were givendifferent levels of blue scorpion venom. After several weeks, the sizeof the tumors was assessed. The tumors in those who received highconcentrations of blue scorpion venom were 45% smaller than the tumorsin those which received no blue scorpion venom. From this data, it maybe concluded that blue scorpion venom inhibits the growth of cancercells in a living organism.

FIG. 5 is an illustration of the results of a study that shows theefficacy of the Makaelian Polarization Process. Horizontally the graphin FIG. 5 represents 24 day testing with urine samples. Vertically thegraph in FIG. 5 represents the percentage of unabsorbed minerals andsupplements in urine.

An Introduction to the Mikaelian Polarized Liquid (MPL) Process.

The human body is composed of about 70% water and 30% solids. Normalmetabolic activity can only occur when cells are at least 65% water.Water is the most important nutrient because it is responsible for somany functions and for the activation of cellular functions by othernutrients. When nutrients have reached the cells, water is necessary forthe cells to function, maintain (catabolic phase) and build and repair(anabolic) phase. These two phases of cellular function are closelyrelated to the cellular water flow or lack of its flow.

Intra-Cellular & Extra-Cellular. There are two types of water in thebody, intra-cellular and extra-cellular. Extra-cellular is the fluidoutside an individual cell while intra-cellular is the fluid foundinside the cell. Both of these types of water are necessary for optimalhealth or wellness of every cell in the body. In order for the cells tobe biologically active they must absorb water. When the cellsover-hydrate it triggers an anabolic phase, one of the healingmechanisms in the body. The anabolic phase is triggered by a positivehydrogen balance, protein synthesis, or growth hormone.

Studies have been performed to test whether there is increasedtransportation of necessary nutrients to the cells by using a MikaelianPolarized Liquid in order to improve the effectiveness of supplementsand medications. The primary goal in this clinical study was to evaluatewhether or not drinking Mikaelian Polarized Liquid with vitamins andminerals every day will increase delivery of nutrients to cells byincreasing cellular hydration as a fundamental indicator of wellness.Each subject was evaluated for baseline numbers on the first day of thestudy. Each subject was retested on the fifteenth and the thirtieth dayof the study. At each office visit we performed: analysis, height,weight, temperature, blood pressure and pulse in addition to urine,blood and saliva samples. Each subject was provided with an instructionsheet indicating how much Mikaelian Polarized Liquid to consume witheach intake of vitamins and minerals. Changes in cellular hydrationinvolve a proprietary combination of specific measurement parametersbased on a mathematical formula to understand any negative deviation,with an emphasis on surface tension, specific gravity and resistivitymeasurements of urine, blood and/or saliva, for each subject in thestudy.

Conclusion of study. Upon completion of this wellness study it has beenindicated that overall these test subjects showed a 27.5% increase inhydration and 58% increase in mineral absorption at a cellular level.The individual's percentages vary from 18-23.5% but all the subjectsshow significant increase in these wellness hydration levels per thespecific method of testing cellular hydration. This study validates thata Mikaelian Polarized Liquid increases mineral and supplement absorptionat the cellular level.

Technical Details on the Mikaelian Polarized Liquid Process.

The first step is determining the correct position of magnetic poles. Itis required to have a regular compass for magnets pole determination.Position a compass on the table next to each magnet. The needle of thecompass will point to the north pole of the magnet. The needle of thecompass is positively charged, thus, it is attracted to the negativepole of the magnet, allowing for identification of that pole. The one ofthe sides of the magnet that will be used for polarization is slowlymoved towards positively charged needle. If highly attracted, thecompass needle indicates that it is the negative pole of the magnet.This will be used for identification. The north pole of the magnet isphysically marked as a (minus) pole or negative charged. The needle ofthe compass is positively charged, thus, it is repulsed by the positivepole of the magnet, allowing for identification of that pole. Theopposite side of the magnet that will be used for polarization is slowlymoved towards the positively charged needle. If highly repulsed, thecompass needle indicates that it is the negative pole of the magnet.This will be used for identification. The south (positive) pole of themagnet is physically marked in red or with plus sign to indicate that itis positively charged.

The second step is preparation of hose and magnetic sandwiches. Twowooden panels of the dimensions ten (10) centimeters in height, one (1)centimeters in width, and sixty (60) centimeters long are prepared. Thepanels can be of any dimension and any non-metallic material withoutdeviating from he scope of the invention. A line of industrial strengthmagnets are glued to these panels using a strong epoxy resin. Themagnets are affixed to the vertical center of the panel in a straightline. The negative/north/minus pole of the magnet is glued face down tothe panel. The positive/south/plus pole of the magnet is face up andexposed. The magnets are lined in succession and preferably have nospacing between their edges. A plastic transparent hose two (2) metersin total length is glued to the vertical center of one of the line ofmagnets on the wooden panels. The hose extends approximately seventy(70) centimeters from either side of the wooden panel. The hose may beopaque and made out of any non-metallic pliable material withoutdeviating from the scope of the invention. Four holes are drilled ineach of the panels. One pair of holes is situated on end of the lengthof the panels; another pair of holes on the opposite end of the lengthof the panels. The two panels are made to face one another. They areconnected by four bolts which are threaded through the four pairs ofholes on either side of the panel. Threaded around each bolt is a springto provide resistance while tightening the bolts. The bolts aretightened to a point where the wooden panels are compressed to apreferred distance no less than 3 mm in separation, compressing theplastic transparent hose in the process.

The third step of the process is connection of hose, pump, andreceptacle. One end of the hose affixed to the magnetic sandwich isconnected to an electric pump. The other end of the hose is deposited ina container. From that container the end of another hose of equaldiameter is placed in the container. The opposite of this hose isaffixed to the electric pump. The pump is preferably an electric pump,but may be any pumping or actuating device that circulates the fluid.

The fourth step is recirculation. The container is filled with distilledwater or a mixture of distilled water and scorpion venom or a mixture ofdistilled water and nutrients or a mixture of distilled water,nutrients, and scorpion venom. The pump is turned on and the liquid ismade to recirculate from the container, through the magnetic sandwich tothe pump and then back to the container at a rate of approximately 190gallons per hour. This process of recirculation is repeated at lengthand will vary based upon the amount of liquid being polarized. Thegreater the amount of liquid; the longer the process of polarization is.The lesser the amount of liquid; the shorter the process of polarizationis.

Intense Magnetic Resistance (IMR). The unique element of MikaelianPolarized Liquid is creation of Intense Magnetic Resistance (IMR) byutilizing similar poled/charged sides of magnets at very closedistances. Other forms of polarization utilize magnetic attraction,while Mikaelian Polarization Process utilizes magnetic repulsion as amechanism for polarization. Liquids flowing through Intense MagneticResistance (IMR) fields are subject to molecular polarization whichstrongly affects the geometric relationships between molecules and theelectromagnetic fields surrounding those molecules in a way which iscommercially significant.

Polarization enhances utilization of water and nutrients. Therealignment of magnetic poles of molecules using Intense MagneticResistance (IMR) enhances absorption and utilization of water,nutrients, and scorpion venom on a cellular level. In particular, thecell membranes of cancer have a distinctive and excessive negativeelectromagnetic charge. The polarization of liquid allows for themolecules within the liquid to be utilized with extreme efficiency bycancer cells, as the positive electromagnetic poles of these moleculesare thoroughly attracted to the excessive negative charge of cancer cellmembranes. Specific to this application, the utilization of scorpionvenom molecules leads to a rapid and efficient triggering of apoptosis(programmed cellular suicide) within cancer cells; thereby acceleratingtheir death and inhibiting the growth of cancerous tumors.

Additional Information on the Cancer Fighting Ability of Blue ScorpionVenom.

Several studies have shown the efficacy of blue scorpion venom intreating and fighting cancer. One of these studies, as discussed above,was a third stage clinical trial involving eight thousand three hundredand two (8,302) patients. In this study, 8,302 patients of a variety ofdifferent stages of cancer were given blue scorpion venom. A variety ofcancers were studied with breast, brain, lung, prostate, and coloncancers being the most common studied. Cancers of the larynx, lung, anduterus showed the greatest benefit over the course of the study.

The researches of the trial used summaries of the clinical history ofeach patient issued by the doctor who tracks the patient throughdifferent medical institutions. Each patient was evaluated monthly.During the evaluation, doctors spoke with the patient or a close familymember and organized their records according to the type of neoplasia(abnormal cell growth).

The conclusions of this study are staggering: no side effects occurredfrom taking this natural product; and 89.55% of patients experienced animproved quality of life from taking blue scorpion venom.

The Eastern Cooperative Oncology Group (ECOG) has a set up a widelyrecognized scale to determine the quality of life of a cancer patientenrolled in a clinical trial. Grade description: “0”=capable of carryingout a normal physical activity without restrictions; “1”=symptomatic,but not hospitalized (restriction on vigorous physical activities, butan outpatient and able to undertake light chores or those of a sedentarynature); “2”=in bed less than 50% of the time, not hospitalized, able tocare for self, but unable to work more than 50% of the time when out ofbed; “3” capable of personal care, but confined to a bed or chair morethan 50% of the time; “4”=completely incapable of any effort, totallyconfined to bed; and “5”=death.

FIG. 6 is an illustration of the results of a study that shows thequality of life for larynx cancer patients that used blue scorpionvenom. As shown in FIG. 6, over 78% of the larynx cancer patients wereasymptomatic (0 on the ECOG scale) or only mildly symptomatic (1 on theECOG scale).

FIG. 7 is an illustration of the results of a study that shows thequality of life for lung cancer patients that used blue scorpion venom.As shown in FIG. 7, over 70% of the lung cancer patients were in ECOGcategories 0, 1, and 2.

FIG. 8 is an illustration of the results of a study that shows thequality of life for uterine cancer patients that used blue scorpionvenom. As shown in FIG. 8, over 65% of the uterine cancer patients werein ECOG categories 0, 1, and 2.

FIG. 9 is an illustration of the results of a study that shows thesurvival rates for the sample types of cancer for patients that usedblue scorpion venom. As shown in FIG. 9, the survival rates of thecancer patients that used blue scorpion venom was extremely high. Over95% of larynx cancer patients, over 80% of lung cancer patients, andover 94% of uterine cancer patients survived during the course of thestudy.

This study shows a substantial improvement for cancer patients that usedblue scorpion venom as part of their cancer treatment regimen. Overall,89.55% of patients in this eight-year clinical trial achieved animprovement in health and quality of life through taking blue scorpionvenom, independent of what stage of cancer they were subject.

Current scientific research. Since the above mentioned clinical trial,additional independent studies, including studies conducted by thepresent inventor, have been conducted. This additional researchvalidates previous results achieved by past research and the clinicaltrial discussed above. Although blue scorpion venom is clearlyeffective, not all people benefit equally from using blue scorpionvenom. Some individuals immediately get well, whereas others show nosigns of improvement. The additional research has developed severalcriteria to systemize all possible aspects which influence theeffectiveness of blue scorpion venom. These factors are the result ofempirical studies, and they lead to the following conclusions as inwhich patients blue scorpion venom tends to have greater benefit.

Current research has found that, independent of stage of cancer, it isof greater benefit to begin using blue scorpion venom as soon as ispossible. Delaying onset of starting blue scorpion venom has not beenshown to be beneficial.

Metastasis. Blue scorpion venom has shown the greatest benefit for thosewhose metastasis has not expanded to include (and heavily compromise thefunction of) major vital organs. Blue scorpion venom still shows benefitfor those whose metastasis has included major vital organs; however,additional factors become significantly more important in these cases.Blue scorpion venom appears to have greater benefits to those patientswhose cancer has not metastasized. Though blue scorpion venom still hasshown amazing results with those patients whose cancer has metastasized,the type of metastasization will influence the degree of effectivenessof blue scorpion venom.

Additional complicating health conditions. Independent of whether apatient's cancer has metastasized, those patients who do not haveadditional chronic health issues have been shown to have more pronouncedbenefits. Chronic non-cancer health issues effecting vital organs (i.e.diabetes, cirrhosis, thyroid disease, etc.) tend to more greatly limitthe full benefit of blue scorpion venom than chronic conditions which donot affect major vital organs. Blue scorpion venom has generally beenshown to be effective even in these cases; however, once again,additional factors take on a heightened degree of importance.

Ongoing exposure to environmental toxins. The root cause of many casesof cancer is over-exposure to any of various carcinogenic toxins foundin our environments. If a person's cancer is rooted in the exposure toenvironmental toxins, it very important for blue scorpion venom'sefficacy that a person remove their self from that high-toxicityenvironment. Otherwise, the root cause of their cancer will continue tobe supported and the benefit of Blue scorpion venom will be limited.

Genetics. Some cancer patients have a genetic (family) history ofcancer. These genetically-influenced cancers are often triggered bycertain environmental and stress-based factors; however, the verygenetic influence of these cancers often limits the effectiveness ofblue scorpion venom. Blue scorpion venom is still highly beneficial inthese cases, but additional conditions need to be addressed. Inaddition, for those who are highly genetically susceptible to thedevelopment of cancer, blue scorpion venom has shown great promise as apreventative measure.

Psychological/environmental stress. Research has found that clientsunder significant amounts of psychological and/or environmental stresstend to have greater challenges with their recovery from cancer thanthose who are able to overcome their psychological stress and/orseparate their self from extreme environmental stress. Blue scorpionvenom has been found to more beneficial for those patients who throughlife choices, changes in lifestyle, and/or counselling are able to limitor overcome excessive psychological/environmental stress. Additionally,endocrinologic and immunologic rationales for a susceptibility to cancerin depressed patients have been proposed. These theories suggest thatstresses, such as depression, lead to excesses of hormones includingadrenal corticosteroids. It is through these corticosteroids thatimmunosuppression is mediated. Evidence for this in humans includesfindings of increased levels of corticosteroids in depressed patientsand lymphocyte suppression in bereaved patients compared tonon-depressed subjects. Patients with compromised immune systems havebeen shown to have higher rates of cancer.

Dietary/nutritional factors. Nutrition and diet play a key role in thedevelopment of many cancers. Nutritional deficiencies and dietaryimbalances (excessive saturated fat, lack of fiber, excessive chemicaladditives, etc.) have been shown to influence the development of cancer.It is essential for the benefit of a blue scorpion venom user that theymaintain a healthy, balanced diet which is conscious of their condition.Blue scorpion venom users who continue to maintain an unhealthy,nutrient deficient diet do not benefit from Blue scorpion venom aspowerfully as those who maintain a health conscious approach tonutrition and diet.

Psychological state/commitment to healing. Multiple studies have shownthat individuals with an optimistic outlook towards their life andhealing show better results than those who have a negative, pessimisticview towards life and the future. Though this is not always the case,still, as a general trend research has seen that those who are fully totheir healing tend to have more positive results than those who havegiven up hope.

Additional information on how blue scorpion venom works in a patient'sBody. Research suggests that blue scorpion venom has a multi-factorialanti-cancer effect. The key to Blue scorpion venom's success is it thatit both directly attacks cancerous cells and triggers biologicalresponses which are anti-cancer in nature, including apoptosis. Bluescorpion venom's has five primary biochemical actions. First, bluescorpion venom stimulates a person's immune system. Research hasconfirmed that in patients who have been administered blue scorpionvenom, an increase in white blood cell count occurs. White blood cellsare responsible for the protective function of the immune system. Withall cancers, a person's immune system plays a crucial role. For manytypes of cancer, the responsiveness of one's immune system plays thedetermining role in that cancer's development. Second, blue scorpionvenom inhibits angiogenesis in cancer tumors. Research confirms that aslowing or reversal of angiogenesis takes place for cancer tumors. It isessential for tumors to develop new blood vessels to feed their need forgrowth. Without these blood vessels, these tumors cannot expand, andfrequently die off. Third, blue scorpion venom inhibits cancer cellfunctionality. Research shows that the venom Leiurus quinquestriatus ofthe Buthidae family of scorpions of inhibits the functionality ofsodium/potassium channels in cell membranes. The blue scorpion(Rhopalurus junceus) is also a member of the Buthidae family. Being ofsame family and possessing biochemical similarities, deductive logicsuggests that the venom of the blue scorpion also inhibits thefunctionality of sodium/potassium channels in cell membranes. All humancells require a balance of sodium and potassium ions to functionproperly. Without this crucial balance, the cell becomes weak and candie. This is the case with cancer cells exposed to blue scorpion venom.Fourth, blue scorpion venom produces cytotoxicity in cancer cells.Research shows that the venom Leiurus quinquestriatus of the Buthidaefamily produces apoptosis in low concentrations. The blue scorpion(Rhopalurus junceus) is also a member of the Buthidae family. Being ofsame family and possessing biochemical similarities, deductive logicsuggests that the venom of the blue scorpion also produces apoptosis.This conclusion is further supported by more recent additional research,in which cancer cells exposed to blue scorpion venom in vitroexperienced cytotoxicity. Apoptosis is concluded because patientsadministered blue scorpion venom do not experience an inflammatoryresponse which normally occurs when necrosis takes place. Instead,patients administered blue scorpion venom experience a powerfulanti-inflammatory response, further suggesting the expression ofapoptosis. Fifth, blue scorpion venom produces a healthy neurologicalresponse to cancer. Research conducted and documented in the eight-yearthird stage clinical trials discussed above, found that patients takingblue scorpion venom consistently exhibited greater sedation, improvedsleep, healthy reflexes, and improved motor skills. These responsesindicate that blue scorpion venom somehow interacts with the nervoussystem in healthy, regulatory way.

Multiple research beginning in the 1950's have shown a correlationbetween extreme nervous system activity (excessive or deficient) andaggressive tumor cell proliferation. By playing a positive regulatoryrole with the nervous system, it is concluded that blue scorpion venominhibits cancer cell proliferation through the support of healthyneurological responsiveness.

Importantly, blue scorpion venom produces cytotoxicity and inhibits cellfunctionality only with cancer cells and not with healthy normal cells.In the eight-year third stage clinical trials discussed above, patientsconsistently experienced anti-inflammatory responses, diminished pain,and improved health while cancerous tumors expressed diminished orreversed cell proliferation. The results of the clinical trials have byindependently confirmed by additional research. Moreover, in vitroexperiments also confirm that cancer cells exposed to blue scorpionvenom experience cytotoxicity.

Blue scorpion venom produces cytotoxicity in cancer cells, but does notproduce cytotoxicity with healthy cells for two reasons. First, cancercells identify proteins in venom as viable nutrient. Cancer cells areknown to aggressively seek out nutrients in their environment to supportrapid cellular division. Blue scorpion venom is extremely rich in avariety of proteins. Cancer cells may misidentify and ingest these venomproteins far more aggressively than healthy cells, thereby creating amuch higher absorption rate. Second, cancer cell potassium channelsprovide greater access to blue scorpion venom absorption. The structureof potassium channels on cancer cells are often distinct from those offound on healthy cells. The unique electrostatic charge of the proteinsin blue scorpion venom may be particularly drawn to the potassiumchannels of cancer cells resulting in much more rapid absorption.

Blue scorpion venom as a cancer treatment. Research confirms that bluescorpion venom is effective in treating a wide variety of cancersincluding cancers of the: prostate; colon; lung; brain; digestive tract;breast; and cervix.

Blue scorpion venom and common health benefits. Research shows thatpatients administered blue scorpion venom frequently experience thefollowing health benefits: improved quality of life; increased survivalrate; and tumor remission lasting five or more years. 89.5% of patientswho have used blue scorpion venom in their treatment have experiencedthese benefits. As stated above, these benefits are dependent upon stageof cancer, genetic issues, condition of vital organs, continued exposureto environmental toxicity, lifestyle choices of the patient, and otherfactors.

Some initial changes in the quality of life of a patient using bluescorpion venom include: minimized negative biological response tochemotherapy and radiation treatment; increased appetite, as well as amid-term increase in body mass; improved quality of sleep; pain relief;and improved patient immune-system response.

Administration of blue scorpion venom. Blue scorpion venom is primarilyadministered orally. Some patients may also have blue scorpion venomadministered via additional different formats. Oral is the most commonform of administration. A patient may be given certain dietaryrestrictions to ensure the greatest effectiveness of blue scorpionvenom. Nasal administration, through a nasal spray, is best for patientswith cancers related to the nervous and skeletal systems. Thisadministration also works well for patients in extreme pain. Forpatients with cancers specifically related to the respiratory system, anaerosol administration of blue scorpion venom has been shown to be mostbeneficial. For cancers related to the rectum or vaginal region,specifically administered drops, suppositories, or douches have had thebest and most comfortable effect. For patients with skin or scalpcancer, a topical ointment of blue scorpion venom has been shown to bemost effective.

The effectiveness of blue scorpion venom. Research concludes that inlung, liver, digestive tract (in general terms), prostate, and breastcancers there are positive clinical and laboratory responses approaching89.5%. Clinical response, does not mean that 89.5% of patient's havebeen totally cured, rather this percentage of patients experience animprovement in quality of life and survival, and in some cases, a totalcure of the disease.

Blue scorpion venom is uniquely effective in the fight against cancer.Blue scorpion venom: is successful in 89.5% of cancer patients; hasundergone a Third Stage clinical trial involving 8,302 patients; has nonegative side effects; is an effective analgesic; has significantanti-inflammatory properties; and in combinational therapy, bluescorpion venom has been used to improve the results with surgery,chemotherapy, radiation, hormone therapy, and other conventionaltreatments.

The following references provide details regarding studies and researchof the efficacy of scorpion venom. These references are incorporated byreference herein as though set forth herein in full.

Bordier C. M., Martinez F. M. M., Salgado S. H. L., Bory P. G. H., PerryB. F., Granado M. R. et al. Composicion antitumoral. Certificado deautor de invencion 1995; #AGIK 35/56.

Castaneda Pasaron O. Toxinas animales: Acciones facilitadoras de latransmision colinergica. Revista Biologia 2000; 14(1): 1-15.

Compton M M. A biochemical hallmark of apoptosis: internucleosomaldegradation of the genome. Cancer Metastasis Rev September 1992;11(2):105-19.

Chen, B. and Ji, Y. Antihyperalgesia effect of BmK A S, a scorpiontoxin, in rat by plantar injection. Brain Res. 2002; 952 2, pp. 322-326.

De Armas L F. Escorpiones del Archipielago Cubano. 1V. Nueva Especie deRhopalurus (Scorpionida: Buthidae). Poeyana 1974; 136:1-12.

Dini L, Coppola S, Ruzittu M T, Ghibelli L. Multiple pathways forapoptotic nuclear fragmentation. Exp Cell Res Mar. 15, 1996;223(2):340-7.

Guan, R. J., Wang, C. G., Wang, M. and Wang, D. C. A depressant insecttoxin with a novel analgesic effect from scorpion Buthus martensiiKarsch. Biochim. Biophys. Acta 2001; 1549 1, pp. 9-18.

Guan, R. J., Wang, M., Wang, D. and Wang, D. C. A new insect neurotoxinAngP1 with analgesic effect from the scorpion Buthus martensi Karsch:purification and characterization. J. Pept. Res. 2001; 58 10, pp. 27-35.

J. I. Kourie and A. A. Shorthouse. Properties of cytotoxicpeptide-formed ion channels. Am J Physiol Cell Physiol 2000; 278:1063-1087.

Liu, Y. F., Ma, R. L., Wang, S. L., Duan, Z. Y., Zhang, J. H., Wu, L. J.and Wu, C. F. Expression of an antitumor-analgesic peptide from thevenom of Chinese scorpion Buthus martensi Karsch in Escherichia coli.Protein Expr Purif. 2003; 27 2, pp. 253-258.

Omran M A. Cytotoxic and apoptotic effects of scorpion Leiurusquinquestriatus venom on 293T and C2 C12 eukaryotic cell lines. J VenomAnim Toxins incl Trop Dis 2003; 9(2):255-76.

Rajendra, W., Arunmozhiarasi, A., Jeyaseelan, K. Toxins inanti-nociception and anti-inflammation. Toxicon; 2004 44 1, pp 1-17.

Xiong, Y. M., Lan, Z. D., Wang, M., Liu, B., Liu, X. Q. Molecularcharacterization of a new insect neurotoxin with an analgesic effect onmice from the scorpion Buthus martensi Karsch. Toxicon 1999; 37 8, pp.1165-1180.

In summary, the present invention is a polarized dilute scorpion venomsolution and a method for administering dilute scorpion venom solution.The polarized dilute scorpion venom solution relieves pain, improvesimmune-system response, treats cancer, prevents cancer, improves qualityof sleep, reduces inflammation, and minimizes negative biologicalresponse to chemotherapy and radiation treatment.

The foregoing description of the preferred embodiment of the inventionhas been presented for the purposes of illustration and description.While multiple embodiments are disclosed, still other embodiments of thepresent invention will become apparent to those skilled in the art fromthe above detailed description, which shows and describes illustrativeembodiments of the invention. As will be realized, the invention iscapable of modifications in various obvious aspects, all withoutdeparting from the spirit and scope of the present invention.Accordingly, the detailed description is to be regarded as illustrativein nature and not restrictive. Also, although not explicitly recited,one or more embodiments of the invention may be practiced in combinationor conjunction with one another. Furthermore, the reference ornon-reference to a particular embodiment of the invention shall not beinterpreted to limit the scope the invention. It is intended that thescope of the invention not be limited by this detailed description, butby the claims and the equivalents to the claims that are appendedhereto.

Except as stated immediately above, nothing which has been stated orillustrated is intended or should be interpreted to cause a dedicationof any component, feature, object, benefit, advantage, or equivalent tothe public, regardless of whether it is or is not recited in the claims.

1. A solution, comprising: a blue scorpion venom; and a distilled water;wherein said blue scorpion venom is diluted in said distilled water tocreate a dilute blue scorpion venom solution; wherein said dilute bluescorpion venom solution is polarized, such that a polarized bluescorpion venom is created.
 2. The solution of claim 1, wherein saiddiluted blue scorpion venom is polarized by a polarization method thatincludes: circulating said diluted blue scorpion venom through one ormore plastic tubes.
 3. The solution of claim 2, wherein saidpolarization method includes: wherein said one or more plastic tubes arealigned with one or more pairs of magnets.
 4. The solution of claim 3,wherein said polarization method includes: wherein said alignment ofsaid one or more pairs of magnets mirror one or more negative poles andone or more positive poles of said magnets, such that said magnets insaid one or more pairs of magnets repel each other.
 5. The solution ofclaim 4, wherein said polarization method includes: wherein said one ormore pairs of magnets are compressed together with a clamp, such thatsaid one or more pairs of magnets are held in place.
 6. The solution ofclaim 5, wherein said polarization method includes: wherein said one ormore pairs of magnets being compressed compress said one or more plastictubes, such that said diluted blue scorpion venom is forced to flowthrough said one or more plastic tubes in close proximity to said one ormore pairs of magnets.
 7. The solution of claim 1, wherein saidpolarized blue scorpion venom provides at least one benefit selectedfrom the group, consisting of: a pain treatment; a reduction of aninflammation; a prevention of a cancer; a prevention of a tumor growth;and a treatment of said cancer.
 8. A solution, comprising: a bluescorpion venom; and a distilled water; wherein said blue scorpion venomis diluted in said distilled water to create a dilute blue scorpionvenom solution; wherein said dilute blue scorpion venom solution ispolarized, such that a polarized blue scorpion venom is created; whereinsaid diluted blue scorpion venom is polarized by a polarization methodthat includes: circulating said diluted blue scorpion venom through oneor more plastic tubes; wherein said one or more plastic tubes arealigned with one or more pairs of magnets; wherein said alignment ofsaid one or more pairs of magnets mirror one or more negative poles andone or more positive poles of said magnets, such that said magnets insaid one or more pairs of magnets repel each other; wherein said one ormore pairs of magnets are compressed together with a clamp, such thatsaid one or more pairs of magnets are held in place; wherein said one ormore pairs of magnets being compressed compress said one or more plastictubes, such that said diluted blue scorpion venom is forced to flowthrough said one or more plastic tubes in close proximity to said one ormore pairs of magnets; wherein said polarized blue scorpion venomprovides at least one benefit selected from the group, consisting of: apain treatment; a reduction of an inflammation; a prevention of acancer; a prevention of a tumor growth; a treatment of said cancer; anincrease in appetite during chemotherapy and radiation treatment; anincrease in body mass during chemotherapy and radiation treatment; aminimization of a negative biological response during chemotherapy andradiation treatment; and an improvement in a quality of sleep.
 9. Amethod of administering a blue scorpion venom, comprising the steps of:diluting a blue scorpion venom; polarizing said dilute blue scorpionvenom; and administering said polarized dilute blue scorpion venom toone or more humans.
 10. The method of claim 9, wherein said dilutingstep is comprised of the steps of: adding a distilled water to said bluescorpion venom to create said dilute blue scorpion venom.
 11. The methodof claim 10, wherein said polarizing step is comprised of the steps of:circulating said dilute blue scorpion venom solution through one or moreplastic tubes; placing one or more pairs of magnets in a series alongsaid one or more plastic tubes; wherein said one or more pairs ofmagnets are placed on one or more opposite sides of said one or moreplastic tubes; wherein said one or more pairs of magnets are aligned,such that one or more negative poles and one or more positive poles ofsaid opposing magnets within said one or more pairs of magnets mirrorand repel each other; compressing said one or more pairs of magnets witha clamp, such that said pairs of magnets remain in place; wherein saidone or more pairs of magnets being compressed compress said one or moreplastic tubes, such that said dilute blue scorpion venom is forced toflow through said one or more plastic tubes in close proximity to saidone or more pairs of magnets.
 12. The method of claim 11, wherein saidadministering step is performed by ingesting said polarized dilute bluescorpion venom by said one or more humans.
 13. The method of claim 11,wherein said administering step is performed by spraying said polarizeddilute blue scorpion venom through a nasal cavity of said one or morehumans.
 14. The method of claim 11, wherein said administering step isperformed by applying said polarized dilute blue scorpion venom on askin surface of said one or more humans.
 15. The solution of claim 11,wherein said polarized dilute blue scorpion venom provides at least onebenefit selected from the group, consisting of: a pain treatment; areduction of an inflammation; a prevention of a cancer; a prevention ofa tumor growth; and a treatment of said cancer.
 16. The method of claim11, wherein said polarized dilute blue scorpion venom boosts an immunesystem response of said one or more humans.
 17. The method of claim 11,wherein said polarized dilute blue scorpion venom boosts a level of anenergy in said one or more humans.